The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics

Oncotarget

Volumn 5, Issue 16, 2014, Pages 7027-7039

  Boesch, Maximilian ^a,b   Zeimet, Alain G ^a   Reimer, Daniel ^a   Schmidt, Stefan ^a   Gastl, Guenther ^a   Parson, Walther ^a   Spoeck, Franziska ^a,b   Hatina, Jiri ^c   Wolf, Dominik ^a,d   Sopper, Sieghart ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

ABC drug transporter; Cancer stem cell; Cancer initiating cell; Epithelial ovarian cancer; Side population; Tumor heterogeneity

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL SUBPOPULATION; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VIVO STUDY; MESOTHELIUM CELL; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; TUMOR GROWTH; ANIMAL; NONOBESE DIABETIC MOUSE; OVARY TUMOR; PATHOLOGY; SCID MOUSE; SIDE POPULATION CELL; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; SIDE-POPULATION CELLS;

EID: 84907086037     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2053     Document Type: Article

References (52)

1. Clevers H. The cancer stem cell: premises, promises and challenges. Nature medicine. 2011; 17(3):313-319.
2. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews Cancer. 2008; 8(10):755-768.
3. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nature reviews Cancer. 2005; 5(4):275-284.
4. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell. 2007; 1(3):313-323.
5. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Muller-Tidow C, Bhatia R, Brunton VG, Koschmieder S and Holyoake TL. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012; 119(6):1501-1510.
6. Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004; 351(24):2519-2529.
7. Cooke SL and Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. The lancet oncology. 2011; 12(12):1169-1174.
8. Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, et al. Ovarian cancer stem cells. Neoplasma. 2012; 59(6):747-755.
9. Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T and Mor G. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of oncology. 2011; 2011:620523.
10. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, Shevde L and Rocconi RP. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clinical & experimental metastasis. 2012; 29(8):939-948.
11. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R and Zou W. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International journal of cancer Journal international du cancer. 2012; 130(1):29-39.
12. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT and Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006; 103(30):11154-11159.
13. Hu L, McArthur C and Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010; 102(8):1276-1283.
14. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB and Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Molecular cancer therapeutics. 2011; 10(2):325-335.
15. Gao MQ, Choi YP, Kang S, Youn JH and Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010; 29(18):2672-2680.
16. Rabindran SK, Ross DD, Doyle LA, Yang W and Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000; 60(1):47-50.
17. Golebiewska A, Brons NH, Bjerkvig R and Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell stem cell. 2011; 8(2):136-147.
18. Greve B, Kelsch R, Spaniol K, Eich HT and Gotte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2012; 81(4):284-293.
19. Jaiswal KR, Xin HW, Anderson A, Wiegand G, Kim B, Miller T, Hari D, Ray S, Koizumi T, Rudloff U, Thorgeirsson SS and Avital I. Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells. Stem cell research. 2012; 9(3):249-260.
20. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362(9387):869-875.
21. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C and Donner DD. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006; 25(14):2060-2069.
22. Zeisberg M and Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119(6):1429-1437.
23. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824):50-56.
24. Pamer E and Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annual review of immunology. 1998; 16:323-358.
25. Strasser A, Jost PJ and Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2):180-192.
26. Domcke S, Sinha R, Levine DA, Sander C and Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nature communications. 2013; 4:2126.
27. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE and Huntsman DG. Type-specific cell line models for type-specific ovarian cancer research. PloS one. 2013; 8(9):e72162.
28. Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A and Herlyn M. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010; 29(46):6115-6124.
29. Masters JR. Human cancer cell lines: fact and fantasy. Nature reviews Molecular cell biology. 2000; 1(3):233-236.
30. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G and Amadori A. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008; 68(14):5658-5668.
31. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH and Frank MH. Identification of cells initiating human melanomas. Nature. 2008; 451(7176):345-349.
32. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-1037.
33. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM and Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008; 456(7222):593-598.
34. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG and Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 2011; 108(16):6468-6473.
35. Stadlmann S, Feichtinger H, Mikuz G, Marth C, Zeimet AG, Herold M, Knabbe C and Offner FA. Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids-evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2014; 24(2):192-200.
36. Huntly BJ and Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature reviews Cancer. 2005; 5(4):311-321.
37. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM and Nelson WG. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008; 68(21):8954-8967.
38. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-1113.
39. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C and Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4):633-644.
40. Dexter DL and Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol. 1986; 4(2):244-257.
41. Turner NC and Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. The lancet oncology. 2012; 13(4):e178-185.
42. Marchitti SA, Brocker C, Stagos D and Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology. 2008; 4(6):697-720.
43. So T, Takenoyama M, Mizukami M, Ichiki Y, Sugaya M, Hanagiri T, Sugio K and Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005; 65(13):5945-5952.
44. Owen-Schaub LB. Fas function and tumor progression: use it and lose it. Cancer Cell. 2002; 2(2):95-96.
45. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E and Peter ME. CD95 promotes tumour growth. Nature. 2010; 465(7297):492-496.
46. Bendall SC and Nolan GP. From single cells to deep phenotypes in cancer. Nature biotechnology. 2012; 30(7):639-647.
47. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H and Daxenbichler G. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. International journal of cancer Journal international du cancer. 1996; 67(6):826-830.
48. Buick RN, Pullano R and Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 1985; 45(8):3668-3676.
49. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E and Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985; 45(10):4970-4979.
50. Wallen JW, Cate RL, Kiefer DM, Riemen MW, Martinez D, Hoffman RM, Donahoe PK, Von Hoff DD, Pepinsky B and Oliff A. Minimal antiproliferative effect of recombinant mullerian inhibiting substance on gynecological tumor cell lines and tumor explants. Cancer Res. 1989; 49(8):2005-2011.
51. Boesch M, Reimer D, Rumpold H, Zeimet AG, Sopper S and Wolf D. DyeCycle Violet used for side population detection is a substrate of P-glycoprotein. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2012; 81(6):517-522.
52. Roederer M, Nozzi JL and Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2011; 79(2):167-174.